Surakanti, Ramu’s team published research in Chemistry – An Asian Journal in 2013 | 30095-98-8

Chemistry – An Asian Journal published new progress about Antibacterial agents. 30095-98-8 belongs to class esters-buliding-blocks, and the molecular formula is C9H9NO4, Name: Methyl 2-(2-nitrophenyl)acetate.

Surakanti, Ramu; Sanivarapu, Sumalatha; Thulluri, Chiranjeevi; Iyer, Pravin S.; Tangirala, Raghuram S.; Gundla, Rambabu; Addepally, Uma; Murthy, Y. L. N.; Velide, Lakshmi; Sen, Subhabrata published the artcile< Synthesis of privileged scaffolds by using diversity-oriented synthesis>, Name: Methyl 2-(2-nitrophenyl)acetate, the main research area is pyrrolidine indoline cyclotryptamine preparation anticancer antibacterial; spiro indoline preparation anticancer antibacterial.

An elegant reagent-controlled strategy has been developed for the generation of a diverse range of biol. active scaffolds from a chiral bicyclic lactam. Reduction of the chiral lactam with LAH or alkylation with LHMDS to trigger different cyclization reactions have been shown to generate privileged scaffolds, such as pyrrolidines, indolines, and cyclotryptamines. Their amenability to substitution allows us to create various compound libraries by using these scaffolds. In silico studies were used to estimate the drug-like properties of these compounds Selected compounds were subjected to anticancer screening by using three different cell lines. In addition, all these compounds were subjected to antibacterial screening to gauge the spectrum of biol. activity that was conferred by our DOS methodol. Gratifyingly, with no addnl. iterative cycles, our method directly generated anticancer compounds with potency at low nanomolar concentrations, as represented by spiroindoline I.

Chemistry – An Asian Journal published new progress about Antibacterial agents. 30095-98-8 belongs to class esters-buliding-blocks, and the molecular formula is C9H9NO4, Name: Methyl 2-(2-nitrophenyl)acetate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics